Targets › CMAH
1 program from 1 company in 1 trial: 1 Phase 1; Genitourinary; next expected readout Oct 2028.
Sialic acids are components of carbohydrate chains of glycoconjugates and are involved in cell-cell recognition and cell-pathogen interactions. That protein has no CMP-N-acetylneuraminate monooxygenase activity and is not able to convert CMP-N-acetylneuraminic acid (CMP-Neu5Ac) into its hydroxylated derivative CMP-N-glycolylneuraminic acid (CMP-Neu5Gc), a sialic acid abundantly expressed at the surface of many cells…. (UniProt, Q9Y471)
Open in Phaseline: the race on CMAH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| United Therapeutics | 10 GE Xenokidney Porcine-derived kidney with intentional genomic alterations (knockout of GGTA1, CMAH, BHMT | GGTA1, CMAH, BHMT, PERV | Phase 1 | ESRD (End-Stage Renal Disease) | Oct 2028 |
ESRD (End-Stage Renal Disease) (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.